A share price of Intellia Therapeutics Inc [NTLA] is currently trading at $13.57, up 11.23%. An important factor to consider is whether the stock is rising or falling in short-term value. The NTLA shares have gain 3.43% over the last week, with a monthly amount drifted -33.61%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on October 28, 2025, when RBC Capital Mkts downgraded its rating to a Sector Perform but kept the price target unchanged to $14 for it. Previously, Bernstein downgraded its rating to Mkt Perform on October 28, 2025. On October 27, 2025, downgrade downgraded it’s rating to Mkt Perform. Guggenheim downgraded its rating to a Neutral. Citizens JMP upgraded its rating to a Mkt Outperform but $33 remained the price target by the analyst firm on October 06, 2025. Wolfe Research upgraded its rating to Outperform for this stock on April 21, 2025, but kept the price target unchanged to $21. In a note dated March 05, 2025, H.C. Wainwright initiated a Buy rating and provided a target price of $30 on this stock.
Intellia Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $5.90 and $28.25. Currently, Wall Street analysts expect the stock to reach $19.4 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $13.57 at the most recent close of the market. An investor can expect a potential return of 42.96% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
Trailing Twelve Months sales for Intellia Therapeutics Inc [NASDAQ:NTLA] were 52.86M which represents 104.76% growth. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -9.69%, Pretax Profit Margin comes in at -9.08%, and Net Profit Margin reading is -9.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.58 and Total Capital is -0.64. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.58 points at the first support level, and at 11.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.12, and for the 2nd resistance point, it is at 14.68.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Intellia Therapeutics Inc [NASDAQ:NTLA] is 5.19. On the other hand, the Quick Ratio is 5.19, and the Cash Ratio is 1.64. Considering the valuation of this stock, the price to sales ratio is 27.56, the price to book ratio is 2.00.
Transactions by insiders
Recent insider trading involved Schultes Birgit C, EVP, Chief Scientific Officer, that happened on Oct 01 ’25 when 31.0 shares were sold. VP, Chief Accounting Officer, Dube Michael P completed a deal on Oct 01 ’25 to sell 1871.0 shares. Meanwhile, Director CHASE WILLIAM J bought 100000.0 shares on Aug 20 ’25.
